CVS Caremark adding 3 knee pain treatments to preferred formulary

CVS Caremark, which manages drug benefits for more than 40 million individuals, is granting preferred access to three Bioventus treatments for pain caused by knee osteoarthritis, according to a Nov. 10 announcement.

Advertisement

Beginning Jan. 1, 2021, Bioventus’ Durolane, Gelsyn-3 and Supartz FX will be included among the four preferred knee osteoarthritis treatment options on the formulary for CVS Caremark members.

Durolane is a single-injection hyaluronic acid-based joint-fluid treatment for patients. Gelsyn-3 is a hyaluronic acid-based joint-fluid treatment requiring three injections, and Supartz is a five-injection hyaluronic acid-based joint-fluid treatment.

More articles on surgery centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.